Erratum: Aspirin plus clopidogrel as secondary prevention after stroke or transient ischemic attack: A systematic review and meta-analysis (Cerebrovascular Diseases (2015 )39 (13-22) DOI: 10.1159/000369778);Aspirin plus clopidogrel as secondary prevention after stroke or transient ischemic attack: A systematic review and meta-analysis

Cerebrovascular Diseases

Volumn 39, Issue 1, 2015, Pages 13-22

  Zhang, Qinghua ^a   Wang, Chao ^b   Zheng, Maoyong ^a   Li, Yanxia ^a   Li, Jincun ^a   Zhang, Liping ^a   Shang, Xiao ^a   Yan, Chuanzhu ^c  

^a Departments of Neurology   (China)

^b SHANDONG UNIVERSITY   (China)

^c SHANDONG UNIVERSITY   (China)

Author keywords

Antiplatelet therapy; Meta analysis; Secondary prevention; Stroke; Transient ischemic attack

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; TICLOPIDINE;

BLEEDING; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; HUMAN; LONG TERM CARE; META ANALYSIS; MONOTHERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; REVIEW; RISK REDUCTION; SECONDARY PREVENTION; SHORT COURSE THERAPY; SYSTEMATIC REVIEW; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; DRUG COMBINATION; ISCHEMIC ATTACK, TRANSIENT; PROCEDURES; RECURRENT DISEASE; STROKE;

ASPIRIN; DRUG THERAPY, COMBINATION; HEMORRHAGE; HUMANS; ISCHEMIC ATTACK, TRANSIENT; PLATELET AGGREGATION INHIBITORS; RECURRENCE; SECONDARY PREVENTION; STROKE; TICLOPIDINE;

EID: 84922283802     PISSN: 10159770     EISSN: 14219786     Source Type: Journal    
DOI: 10.1159/000381818     Document Type: Erratum

References (48)

1. Mathers CD, Loncar D: Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006; 3:e442.
2. Boysen G, Truelsen T: Prevention of recurrent stroke. Neurol Sci 2000; 21: 67-72.
3. Algra A, van Gijn J: Aspirin at any dose above 30 mg offers only modest protection after cerebral ischaemia. J Neurol Neurosurg Psychiatry 1996; 60: 197-199.
4. Antithrombotic Trialists' Collaboration: Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86.
5. Warlow C: Secondary prevention of stroke. Lancet 1992; 339: 724-727.
6. Antithrombotic Trialists' Collaboration: Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849-1860.
7. Herbert JM, Dol F, Bernat A, Falotico R, Lale A, Savi P: The antiaggregating and antithrombotic activity of clopidogrel is potentiated by aspirin in several experimental models in the rabbit. Thromb Haemost 1998; 80: 512-518.
8. Makkar RR, Eigler NL, Kaul S, Frimerman A, Nakamura M, Shah PK, et al: Effects of clopidogrel, aspirin and combined therapy in a porcine ex vivo model of high-shear induced stent thrombosis. Eur Heart J 1998; 19: 1538-1546.
9. Serebruany VL, Malinin AI, Ziai W, Pokov AN, Bhatt DL, Alberts MJ, et al: Effects of clopidogrel and aspirin in combination versus aspirin alone on platelet activation and major receptor expression in patients after recent ischemic stroke: for the Plavix Use for Treatment of Stroke (PLUTO-Stroke) trial. Stroke 2005; 36: 2289-2292.
10. Wang Y, Wang Y, Zhao X, Liu L, Wang D, Wang C, et al: Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med 2013; 369: 11-19.
11. Hankey GJ: Dual antiplatelet therapy in acute transient ischemic attack and minor stroke. N Engl J Med 2013; 369: 82-83.
12. Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M, et al: Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 2004; 364: 331-337.
13. Kennedy J, Hill MD, Ryckborst KJ, Eliasziw M, Demchuk AM, Buchan AM; FASTER Investigators: Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial. Lancet Neurol 2007; 6: 961-969.
14. Hankey GJ, Johnston SC, Easton JD, Hacke W, Mas JL, Brennan D, et al: Effect of clopidogrel plus ASA vs. ASA early after TIA and ischaemic stroke: a substudy of the CHARISMA trial. Int J Stroke 2011; 6: 3-9.
15. SPS3 Investigators; Benavente OR, Hart RG, McClure LA, Szychowski JM, Coffey CS, et al: Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. N Engl J Med 2012; 367: 817-825.
16. European Stroke Organisation (ESO) Executive Committee; ESO Writing Committee: Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis 2008; 25: 457-507.
17. Wang YJ, Zhang SM, Zhang L, Wang CX: Chinese guidelines for the secondary prevention of ischemic stroke and transient ischemic attack 2010. CNS Neurosci Ther 2012; 18: 93-101.
18. Kern R, Nagayama M, Toyoda K, Steiner T, Hennerici MG, Shinohara Y: Comparison of the European and Japanese guidelines for the management of ischemic stroke. Cerebrovasc Dis 2013; 35: 402-418.
19. Kernan WN, Ovbiagele B, Black HR, Bravata DM, Chimowitz MI, Ezekowitz MD, et al: Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2014; 45: 2160-2236.
20. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al: Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1-12.
21. Lee M, Saver JL, Hong KS, Rao NM, Wu YL, Ovbiagele B: Risk-benefit profile of long-term dual-versus single-antiplatelet therapy among patients with ischemic stroke: a systematic review and meta-analysis. Ann Intern Med 2013; 159: 463-470.
22. Bal Dit Sollier C, Crassard I, Simoneau G, Bergmann JF, Bousser MG, Drouet L: Effect of the thromboxane prostaglandin receptor antagonist terutroban on arterial thrombogenesis after repeated administration in patients treated for the prevention of ischemic stroke. Cerebrovasc Dis 2009; 28: 505-513.
23. Markus HS, Droste DW, Kaps M, Larrue V, Lees KR, Siebler M, et al: Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using doppler embolic signal detection: the Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) trial. Circulation 2005; 111: 2233-2240.
24. Wong KS, Chen C, Fu J, Chang HM, Suwanwela NC, Huang YN, et al: Clopidogrel plus aspirin versus aspirin alone for reducing embolisation in patients with acute symptomatic cerebral or carotid artery stenosis (CLAIR study): a randomised, open-label, blindedendpoint trial. Lancet Neurol 2010; 9: 489-497.
25. Benavente OR, White CL, Pearce L, Pergola P, Roldan A, Benavente MF, et al: The Secondary Prevention of Small Subcortical Strokes (SPS3) study. Int J Stroke 2011; 6: 164-175.
26. Diener HC, Weber R: Clopidogrel added to aspirin adds no benefit but bleeding risk in patients with recent lacunar stroke. Stroke 2013; 44: 861-863.
27. Wang Y, Johnston SC; CHANCE Investigators: Rationale and design of a randomized, double-blind trial comparing the effects of a 3-month clopidogrel-aspirin regimen versus aspirin alone for the treatment of high-risk patients with acute nondisabling cerebrovascular event. Am Heart J 2010; 160: 380-386.e1.
28. Meyer DM, Albright KC, Allison TA, Grotta JC: LOAD: a pilot study of the safety of loading of aspirin and clopidogrel in acute ischemic stroke and transient ischemic attack. J Stroke Cerebrovasc Dis 2008; 17: 26-29.
29. Chimowitz MI, Lynn MJ, Derdeyn CP, Turan TN, Fiorella D, Lane BF, et al: Stenting versus aggressive medical therapy for intracranial arterial stenosis. N Engl J Med 2011; 365: 993-1003.
30. King A, Bath PM, Markus HS: Clopidogrel versus dipyridamole in addition to aspirin in reducing embolization detected with ambulatory transcranial Doppler: a randomized trial. Stroke 2011; 42: 650-655.
31. Kwon SU, Hong KS, Kang DW, Park JM, Lee JH, Cho YJ, et al: Efficacy and safety of combination antiplatelet therapies in patients with symptomatic intracranial atherosclerotic stenosis. Stroke 2011; 42: 2883-2890.
32. Grau AJ, Reiners S, Lichy C, Buggle F, Ruf A: Platelet function under aspirin, clopidogrel, and both after ischemic stroke: a case-crossover study. Stroke 2003; 34: 849-854.
33. Helgason CM, Grossi E, Pandey D, Valika A, Cursio J, Brace LD: Platelet aggregation and recruitment with aspirin-clopidogrel therapy. Cerebrovasc Dis 2008; 25: 392-400.
34. Payne DA, Jones CI, Hayes PD, Thompson MM, London NJ, Bell PR, et al: Beneficial effects of clopidogrel combined with aspirin in reducing cerebral emboli in patients undergoing carotid endarterectomy. Circulation 2004; 109: 1476-1481.
35. Zhao L, Fletcher S, Weaver C, Leonardi-Bee J, May J, Fox S, et al: Effects of aspirin, clopidogrel and dipyridamole administered singly and in combination on platelet and leucocyte function in normal volunteers and patients with prior ischaemic stroke. Thromb Haemost 2005; 93: 527-534.
36. Serebruany VL, Malinin AI, Pokov AN, Hanley DF: Antiplatelet profiles of the fixed-dose combination of extended-release dipyridamole and low-dose aspirin compared with clopidogrel with or without aspirin in patients with type 2 diabetes and a history of transient ischemic attack: a randomized, single-blind, 30-day trial. Clin Ther 2008; 30: 249-259.
37. Geraghty OC, Paul NL, Chandratheva A, Rothwell PM: Low risk of rebound events after a short course of clopidogrel in acute TIA or minor stroke. Neurology 2010; 74: 1891-1896.
38. Sanofi: COMbination of Clopidogrel and Aspirin for Prevention of Early Recurrence in Acute Atherothrombotic Stroke (COMPRESS). ClinicalTrials. gov. http://clinicaltrials.gov/show/NCT00814268 (first received December 23, 2008).
39. University of California, San Francisco: Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial. Clinical-Trials.gov. http://clinicaltrials.gov/ct2/show/NCT00991029 (first received October 6, 2009).
40. Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, et al: Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006; 354: 1706-1717.
41. Gaciong Z: [Clopidogrel and aspirin versus aspirin alone in prevention of atherothrombotic events. The results of CHARISMA study]. Kardiol Pol 2006; 64: 548-551; discussion 551-552.
42. Palacio S, Hart RG, Pearce LA, Anderson DC, Sharma M, Birnbaum LA, et al: Effect of addition of clopidogrel to aspirin on stroke incidence: meta-analysis of randomized trials. Int J Stroke 2013, DOI: 10.1111/ijs.12050.
43. Huang Y, Li M, Li JY, Li M, Xia YP, Mao L, et al: The efficacy and adverse reaction of bleeding of clopidogrel plus aspirin as compared to aspirin alone after stroke or TIA: a systematic review. PLoS One 2013; 8:e65754.
44. Geeganage CM, Diener HC, Algra A, Chen C, Topol EJ, Dengler R, et al: Dual or mono antiplatelet therapy for patients with acute ischemic stroke or transient ischemic attack: systematic review and meta-analysis of randomized controlled trials. Stroke 2012; 43: 1058-1066.
45. Wong KS, Wang Y, Leng X, Mao C, Tang J, Bath PM, et al: Early dual versus mono antiplatelet therapy for acute non-cardioembolic ischemic stroke or transient ischemic attack: an updated systematic review and meta-analysis. Circulation 2013; 128: 1656-1666.
46. Li X, Zhou G, Zhou X, Zhou S: The efficacy and safety of aspirin plus dipyridamole versus aspirin in secondary prevention following TIA or stroke: a meta-analysis of randomized controlled trials. J Neurol Sci 2013; 332: 92-96.
47. Martens RJ, Vink H, van Oostenbrugge RJ, Staals J: Sublingual microvascular glycocalyx dimensions in lacunar stroke patients. Cerebrovasc Dis 2013; 35: 451-454.
48. Lavall PC, Labreuche J, Faille D, Huisse MG, Nicaise-Roland P, Dehoux M, et al: Circulating markers of endothelial dysfunction and platelet activation in patients with severe symptomatic cerebral small vessel disease. Cerebrovasc Dis 2013; 36: 131-138.